机译:发现新的Thieno [3,2-D]嘧啶衍生物针对EGFR(L858R / T790M)NSCLC的构造受约束策略
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Sch Basic Med Sci Dept Pharmacol Zhengzhou 450001 Peoples R China;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Zhengzhou Univ Key Lab Adv Pharmaceut Technol State Key Lab Esophageal Canc Prevent &
Treatment;
Thieno3; 2-dpyrimidine; Quinolin-2(1H)-Ones; EGFR inhibitors; Lung cancer;
机译:发现新的Thieno [3,2-D]嘧啶衍生物针对EGFR(L858R / T790M)NSCLC的构造受约束策略
机译:发现5-(甲硫基)嘧啶衍生物作为L858R / T790M突变体选择表皮生长因子受体(EGFR)抑制剂
机译:发现新的嘧啶-5-碳腈衍生物作为靶向EGFR〜(WT)和EGFR〜(T790M)的抗癌剂
机译:目标约束构象搜索的细分方法
机译:噻吩并[3,2-d]-和吡咯并[3,2-d]嘧啶及其C-核苷的合成及生物学评价
机译:依鲁替尼选择性且不可逆地靶向EGFR(L858RDel19)突变体但对EGFR(T790M)突变体NSCLC细胞具有中度耐药性
机译:在EGFR-TKIS治疗过程中,NSCLC在NSCLC中的T790M之间的改变:基于文献的汇总分析